Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
EU lawmakers approved new drug rules on Dec. 11, 2025, boosting innovation and access with extended protections, subscription pricing, and stronger generics and shortage safeguards.
EU lawmakers have agreed on a major overhaul of pharmaceutical regulations, setting new rules to balance innovation and patient access.
Drugs will get up to 11 years of combined data and market protection, with extensions for unmet medical needs or rare diseases.
A subscription model decouples revenue from sales, and countries can demand supply with penalties for non-compliance.
The reform includes faster EMA processing, digital patient leaflets, and mandatory shortage prevention plans.
It also introduces transferable vouchers for priority antimicrobials and strengthens generics access through clearer patent exemptions.
The deal, finalized December 11, 2025, aims to boost Europe’s drug competitiveness and health security.
Los legisladores de la UE aprobaron nuevas reglas de medicamentos el 11 de diciembre de 2025, impulsando la innovación y el acceso con protecciones extendidas, precios de suscripción y genericos más fuertes y salvaguardas de escasez.